Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lethal Congenital Contracture Syndrome 2 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 10fludarabine 7pomalidomide 5pembrolizumab 5Dexamethasone 5daratumumab 4obinutuzumab 3glofitamab 3fludarabine phosphate 3abemaciclib 3Rituximab 3Melphalan 3Immunotherapy, Adoptive 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2pirtobrutinib 2palbociclib 2cemiplimab 2blinatumomab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Nivolumab 2Mesna 2Letrozole 2Injections 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Itraconazole × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡